Pharmacotherapy of Gastrointestinal Inflammation
Springer Science & Business Media, Nov 27, 2003 - Medical - 146 pages
In recent years, the area of pharmacotherapy of GI inflammation has witnessed important progress, with new drugs and therapeutic approaches being introduced. The volume reviews the pharmacotherapy of selected gastrointestinal inflammatory conditions chosen on the basis of their clinical importance and/or the areas where important and exciting progress has been made recently. Besides discussing current pharmacotherapy to treat the most important GI inflammation conditions, the book also indicates possible future therapeutic avenues likely to become available in a few years.
The book is of interest to various sectors of the scientific community ranging from clinicians to pharmacologists and from biochemists to microbiologists, who will find it a useful tool for their clinical practice and research activity.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Pharmacotherapy of Helicobacter pyloriassociated gastritis
Novel therapeutic approaches
Current and future therapy of chronic hepatitis
Treatment and prevention of antibioticassociated colitis
Other editions - View all
acid active Crohn's disease agents Aliment Pharmacol Ther anti anti-inflammatory antibiotic antibiotic-associated diarrhoea antibodies antigen antimicrobial antiviral aspirin autoimmune hepatitis boulardii cancer CD patients cells chronic hepatitis cirrhosis clarithromycin Clin clinical trials colon controlled corticosteroids Crohn's disease cytokines decrease diarrhoea difficile dose drugs effects efficacy epithelial etanercept gastric gastritis Gastroenterol Gastroenterology gastrointestinal gene Helicobacter pylori heparin histological human IFN-a IFN-y immune response immune system induced Inflamm Bowel inflammatory bowel disease infliximab infusion inhibition inhibitors intestinal lamivudine levels liver lymphocytes mechanisms mediated metronidazole mg/kg mice molecules mucosal natalizumab nitric oxide NO-aspirins non-tolerized NSAIDs open-label oral tolerance pathogenic Phase placebo present proteins pylori infection recombinant regimen remission ribavirin role Rutgeerts serum Soldato steroid suppression T-cell thalidomide therapeutic therapy tion tissue TNBS tolerance induction tolerized rats toxicity treated treatment UC patients ulcerative colitis viral virus vitro weeks